CEDAR KNOLLS, N.J.,
April 3, 2018 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), a bionutrition company and owner of
Fortetropin®, the natural product that helps build lean
muscle in conjunction with resistance training, announced that the
Company's Chief Executive Officer, Joseph
Mannello, will present at the MicroCap Conference on
Tuesday, April 10th at 12:30 p.m. Eastern Time at the Essex House in
New York City. Mr. Mannello will
also be available to participate in one-on-one meetings with
investors who are registered to attend the conference.
"We are excited about the opportunity to meet with investors to
discuss our recent business developments," said Mr. Mannello.
"These include our growing portfolio of research projects to
further explore the benefits of our proprietary ingredient,
Fortetropin®; our new Fortetropin®-based pet
product; and additional brand development initiatives that position
us to tap into the $28
billion-and-rising fitness and sports nutrition market, as
well as the active senior population which is expected to double
over the next 30 years."
To request free registration, please go to the conference
website (https://microcapconf.com/), and click the "Registration"
button.
About MYOS RENS Technology Inc.
MYOS RENS Technology Inc. (MYOS), "The Muscle Company™", is a
Cedar Knolls, NJ-based
bionutrition company that develops and markets products that
improve muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin® has been clinically
shown to increase muscle size and lean body mass in conjunction
with resistance training. MYOS believes Fortetropin® has
the potential to redefine existing standards of physical health and
wellness. For more information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements in this release that are not historical facts are
forward-looking statements. Actual results may differ materially
from those projected or implied in any forward-looking statements.
Such statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the successful launch of our products,
including Qurr® products, the success of our research
and development, the results of the clinical evaluation of
Fortetropin® and its effects, the ability to enter into
new partnership opportunities and the success of our existing
partnerships, the ability to generate revenue and
cash flow from sales of our products, the ability to continue
increasing our revenue and gross profit margins, the ability to
achieve a sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to update or revise any
forward-looking statement for events or circumstances after
the date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-to-present-at-the-microcap-conference-april-10-in-new-york-city-at-the-essex-house-300623787.html
SOURCE MYOS RENS Technology Inc.